The second half of 2026 is well under way, signaling a shift in focus for state policy activities as the majority of states have now completed their legislative activity for […] The post A Mid-Year State Policy Recap appeared first on EveryLife Foundation for Rare Diseases.

Original title: “A Mid-Year State Policy Recap”

The U.S. Food and Drug Administration today announced two actions targeting petroleum-based color additives in food, continuing the agency’s broader efforts to Make America Healthy Again.

Original title: “FDA Takes Further Steps to Remove Outdated Authorizations for Color Additives in Food”

A Congressional advisory panel recommends the U.S. government put supportive policies in place for rare disease drug development, such as a finalized platform designation from the FDA and the allowance of novel trial designs for small patient populations.

Original title: “US ‘eroding’ lead in rare diseases a matter of national security: Report”

Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

Original title: “S 1041: Affordable Prescriptions for Patients Act”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9696: Saving Lives and Reducing Health Care Waste by Improving Diagnosis in Medicine Act”

Motion to reconsider laid on the table Agreed to without objection.

Original title: “HR 4541: To reauthorize the Young Women’s Breast Health Education and Awareness Requires Learning Young Act of 2009.”

The Food and Drug Administration (FDA, Agency, or we) has determined that RASUVO (methotrexate) solution, 27.5 milligrams (mg)/ 0.55 milliliter (mL) (27.5 mg/0.55 mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for RASUVO (methotrexate) solution, 27.5 mg/0.55 mL (27.5 mg/0.55 mL), if all other legal and regulatory requirements are met.

Original title: “Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness”

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Agriculture, Oversight and Government Reform, Education and Workforce, the Judiciary, the Budget, Veterans' Affairs, Natural Resources, Armed Services, Homeland Security, Financial Services, Transportation and Infrastructure, and Foreign Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 9877: Health Equity and Accountability Act of 2026”

The Administration for Children and Families (ACF) intends to request from the Office of Management and Budget (OMB) an extension of approval for an umbrella generic clearance for information collections related to ACF program office monitoring activities. ACF programs promote the economic and social well-being of families, children, individuals, and communities. The Generic for ACF Program Monitoring Activities allows ACF program offices to collect standardized information from recipients that

Original title: “Submission for Office of Management and Budget Review; Generic for Administration for Children and Families Program Monitoring Activities”

Referred to the House Committee on Energy and Commerce.

Original title: “HRES 1437: Recognizing that equity, diversity, and inclusion in federally funded health research is necessary to enhance scientific excellence, and ensure equitable outcomes for patients in the United States.”

Motion to reconsider laid on the table Agreed to without objection.

Original title: “HR 2821: FDA Modernization Act 3.0”

Motion to reconsider laid on the table Agreed to without objection.

Original title: “HR 2001: Action for Dental Health Act”

Motion to reconsider laid on the table Agreed to without objection.

Original title: “HR 8823: Putting Patients First by Strengthening Provider Accountability in FECA Act”

The biopharma industry would do well to re-embrace the 505(b)(2) path, which allows sponsors to draw on previous findings around an existing drug even as they propose modifications to it.

Original title: “The FDA’s 505(b)(2) pathway is an underestimated engine of value creation”

Referred to the House Committee on Energy and Commerce.

Original title: “HR 9774: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 177: Protect Funding for Women's Health Care Act”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 5012: Welcome Back to the Health Care Workforce Act”

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Original title: “S 4989: Saving Lives and Reducing Health Care Waste by Improving Diagnosis in Medicine Act”

Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.

Original title: “S 4987: Pharmaceutical Investment Oversight and Accountability Act”

Referred to the House Committee on Education and Workforce.

Original title: “HR 9754: Health Claim Denial Transparency Act”